{"altmetric_id":2866472,"counts":{"readers":{"mendeley":33,"citeulike":0,"connotea":0},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1},"total":{"posts_count":7},"twitter":{"unique_users_count":5,"unique_users":["andybreathe","JTOonline","OncoPolmoneIEO","MLPOncoData","MrPug94"],"posts_count":6}},"selected_quotes":["PRONOUNCE Trial Pem+Cb did not produce significantly better compared with Pac+Cb+Bev in mNSCLC.","#PRONOUNCE: Advanced Nonsquamous #NSCLC #MOREoncology"],"citation":{"abstract":"PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).","abstract_source":"pubmed","altmetric_jid":"4f6fa62b3cf058f610007efc","authors":["Zinner RG","Obasaju CK","Spigel DR","Weaver RW","Beck JT","Waterhouse DM","Modiano MR","Hrinczenko B","Nikolinakos PG","Liu J","Koustenis AG","Winfree KB","Melemed SA","Guba SC","Ortuzar WI","Desaiah D","Treat JA","Govindan R","Ross HJ","Ralph G. Zinner","Coleman K. Obasaju","David R. Spigel","Robert W. Weaver","J. Thaddeus Beck","David M. Waterhouse","Manuel R. Modiano","Borys Hrinczenko","Petros G. Nikolinakos","Jingyi Liu","Andrew G. Koustenis","Katherine B. Winfree","Symantha A. Melemed","Susan C. Guba","Waldo I. Ortuzar","Durisala Desaiah","Joseph A. Treat","Ramaswamy Govindan","Helen J. Ross"],"doi":"10.1097\/jto.0000000000000366","endpage":"142","first_seen_on":"2014-11-09T07:24:36+00:00","funders":["niehs"],"issns":["1556-0864","15560864"],"issue":"1","journal":"Journal of Thoracic Oncology","last_mentioned_on":1483089700,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25371077?dopt=Abstract","http:\/\/journals.lww.com\/jto\/Fulltext\/2015\/01000\/PRONOUNCE__Randomized,_Open_Label,_Phase_III_Study.16.aspx","http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4276572\/pdf\/jto-10-134.pdf","https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4276572\/","http:\/\/dx.doi.org\/10.1097\/JTO.0000000000000366"],"pmid":"25371077","pubdate":"2014-11-06T00:00:00+00:00","publisher":"Wolters Kluwer Health","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Cardiovascular Medicine And Haematology","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"134","subjects":["neoplasms","pulmonarymedicine"],"title":"PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415307826","volume":"10","mendeley_url":"http:\/\/www.mendeley.com\/research\/pronounce-randomized-openlabel-phase-iii-study-firstline-pemetrexed-carboplatin-followed-maintenance"},"altmetric_score":{"score":5.5,"score_history":{"1y":0.5,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":5.5},"context_for_score":{"all":{"total_number_of_other_articles":7958342,"mean":6.7226589717569,"rank":1387853,"this_scored_higher_than_pct":82,"this_scored_higher_than":6563758,"rank_type":"exact","sample_size":7958342,"percentile":82},"similar_age_3m":{"total_number_of_other_articles":202934,"mean":7.8954644143635,"rank":39327,"this_scored_higher_than_pct":80,"this_scored_higher_than":163419,"rank_type":"exact","sample_size":202934,"percentile":80},"this_journal":{"total_number_of_other_articles":1963,"mean":5.3465688073394,"rank":233,"this_scored_higher_than_pct":88,"this_scored_higher_than":1730,"rank_type":"exact","sample_size":1963,"percentile":88},"similar_age_this_journal_3m":{"total_number_of_other_articles":92,"mean":6.4451648351648,"rank":15,"this_scored_higher_than_pct":83,"this_scored_higher_than":77,"rank_type":"exact","sample_size":92,"percentile":83}}},"demographics":{"poster_types":{"member_of_the_public":4,"researcher":1},"users":{"twitter":{"cohorts":{"Scientists":1,"Science communicators (journalists, bloggers, editors)":1,"Members of the public":3}},"mendeley":{"by_status":{"Professor > Associate Professor":3,"Student  > Doctoral Student":3,"Researcher":7,"Student  > Ph. D. Student":1,"Student  > Master":6,"Other":7,"Student  > Bachelor":5,"Lecturer":1},"by_discipline":{"Medicine and Dentistry":17,"Social Sciences":1,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":3,"Nursing and Health Professions":5,"Biochemistry, Genetics and Molecular Biology":1,"Unspecified":4,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"IT":1,"CO":1,"US":1},"mendeley":{"EC":1,"JP":1,"CH":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/andybreathe\/status\/531346465919365120","license":"datasift","citation_ids":[2866472],"posted_on":"2014-11-09T07:24:04+00:00","author":{"name":"Andreas-Cl. Hoffmann","url":"http:\/\/www.more-oncology.de\/","image":"https:\/\/pbs.twimg.com\/profile_images\/827830830995234817\/Bbly2akM_normal.jpg","description":"Hematologist, Medical Oncologist, Cancer Researcher, Follow-up Care After Cancer Treatment, Oncology Rehabilitation, tweets and opinions expressed are my own","id_on_source":"andybreathe","tweeter_id":"220780239","geo":{"lt":null,"ln":null},"followers":421},"tweet_id":"531346465919365120"},{"url":"https:\/\/twitter.com\/JTOonline\/status\/550386879145603072","license":"datasift","citation_ids":[2866472],"posted_on":"2014-12-31T20:23:52+00:00","author":{"name":"JTO","url":"http:\/\/www.jto.org","image":"https:\/\/pbs.twimg.com\/profile_images\/691742204675563520\/QRXaEkPc_normal.jpg","description":"The JTO is the official journal of @IASLC and the primary source for information on the detection, prevention, diagnosis and treatment of thoracic malignancies.","id_on_source":"JTOonline","tweeter_id":"188832334","geo":{"lt":null,"ln":null},"followers":1036},"tweet_id":"550386879145603072"},{"url":"https:\/\/twitter.com\/JTOonline\/status\/555342063017816064","license":"datasift","citation_ids":[2866472],"posted_on":"2015-01-14T12:34:00+00:00","author":{"name":"JTO","url":"http:\/\/www.jto.org","image":"https:\/\/pbs.twimg.com\/profile_images\/691742204675563520\/QRXaEkPc_normal.jpg","description":"The JTO is the official journal of @IASLC and the primary source for information on the detection, prevention, diagnosis and treatment of thoracic malignancies.","id_on_source":"JTOonline","tweeter_id":"188832334","geo":{"lt":null,"ln":null},"followers":1036},"tweet_id":"555342063017816064"},{"url":"https:\/\/twitter.com\/OncoPolmoneIEO\/status\/555344493655126016","license":"datasift","rt":["JTOonline"],"citation_ids":[2866472],"posted_on":"2015-01-14T12:43:39+00:00","author":{"name":"OncoPolmoneIEO","url":"http:\/\/www.ieo.it","image":"https:\/\/pbs.twimg.com\/profile_images\/545884150150868992\/JeoR9r5K_normal.png","description":"Division of Thoracic Oncology - European Institute of Oncology. Director: F de Marinis, MD #LCSM","id_on_source":"OncoPolmoneIEO","tweeter_id":"2915560725","geo":{"lt":45.46427,"ln":9.18951,"country":"IT"},"followers":158},"tweet_id":"555344493655126016"},{"url":"http:\/\/twitter.com\/MLPOncoData\/statuses\/699720468123799552","license":"gnip","citation_ids":[2866472],"posted_on":"2016-02-16T22:22:14+00:00","author":{"name":"MLPOncoData","image":"https:\/\/pbs.twimg.com\/profile_images\/1768351267\/image_normal.jpg","description":"Medicina Interna - Oncolog\u00eda Cl\u00ednica","id_on_source":"MLPOncoData","tweeter_id":"469235472","geo":{"lt":6.25184,"ln":-75.56359,"country":"CO"},"followers":46},"tweet_id":"699720468123799552"},{"url":"http:\/\/twitter.com\/MrPug94\/statuses\/814763373149552640","license":"gnip","citation_ids":[2866472],"posted_on":"2016-12-30T09:21:40+00:00","author":{"name":"Brian Shields","url":"http:\/\/www.latimes.com\/business\/la-fi-genentech-tarceva-settlement-20160607-snap-story.html","image":"https:\/\/pbs.twimg.com\/profile_images\/753058072768098304\/6Fqger_P_normal.jpg","description":"Former Army Aviator, USMA grad, Cancer Advocate, Pharma Whistleblower","id_on_source":"MrPug94","tweeter_id":"164254921","geo":{"lt":37.25022,"ln":-119.75126,"country":"US"},"followers":6117},"tweet_id":"814763373149552640"}],"policy":[{"title":"Lung cancer: diagnosis and management: Appendix A: Decision matrix","url":"https:\/\/www.nice.org.uk\/guidance\/cg121\/evidence\/appendix-a-decision-matrix-2371717550","license":"public","citation_ids":[2783078,1821279,20564648,20564652,17971817,2867673,5610569,1228016,2224453,862167,1897981,2779695,3741883,2826264,2030373,3022681,2081155,2743472,1684354,15784095,1500269,20564742,4158745,2779696,20564768,20564774,17891335,1984675,3056376,2043712,1187597,1739454,2266535,2888543,20564807,2357666,1572283,2005478,7400529,1390600,1298322,1638530,2829857,1003804,2180675,1287116,2614327,20564887,4612469,2045306,2574589,1560802,1930648,20564929,17891620,15775032,15775041,15775042,2414003,15775090,2631992,2247226,2234507,2155825,20564965,1075719,2887846,936664,20564983,20564993,20564997,15775107,2347563,2506685,720738,20565021,3708678,1304098,3104468,15265637,20565042,925069,1949736,15775035,1949787,5579236,2866472,20565084,20565089,20565097,1171019,1155741,3017788,20565125,2317751,2007085,1911744,20565158,20565168,6263190,2014722,2091687,20565197,1002756,20565200,17993351,826915,2103607,20565220,895449,9707399,15775043,663865,1013882,20565241,933958,17925036,2342521,6870697,20565269,20565278,2653985,2345759,20565293,2720770,2552779,2662567,20565315,1086132,20565329,20565333,20565338,2610940,921762,1964628,12275268,2803264,2018697,2187882,3070293,754668,20565380,20565390,860332,20565396,20565404,20565412,1217546,1622889,20565431,15775078,938640,1399529,20565445,20565450,4215029,20565457,20565464,17894792,20565474,20565483,2548163,20565495,18346360,20565502,20565510,1008389,18346371,2429752,3435833,20565534,2369233,20565546,1711506,1780014,2340575,4409038,1392145,16030462,1942767,20565578,1844446,718729,15775053,15775049,15775056,15775059,5976064,3070293,2803264,6201650],"posted_on":"2016-03-17T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/cg121\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-7dd5bf7959f6d0d4b2d188488966873acebb97683e59f17fb430b6a23062bcb5.jpg"}}]}}